Catumaxomab (anti-CD3&EpCAM), a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab (anti-CD3&EpCAM) region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab (anti-CD3&EpCAM) can be used for anti-tumor research, especially epithelial cancers. Purity ≥90% (SDS-PAGE&SEC) Endotoxin Level ≤1.0EU/mg Protein Function CD3: The CD3 complex mediates signal transduction. EpCAM:May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E
Product Properties
Isotype
Mouse IgG2a
Light Chain Type
kappa
SDS-PAGE
146.73 kDa
Purification Method
Protein A purified
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
1.Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.. J Immunol, 163 (3):(1246-52). [PMID:10415020][10.1021/op500134e]
2.Riesenberg R, Buchner A, Pohla H, Lindhofer H. (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).. J Histochem Cytochem, 49 (7):(911-7). [PMID:11410615][10.1021/op500134e]
3.Ruf P, Lindhofer H. (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.. Blood, 98 (8):(2526-34). [PMID:11588051][10.1021/op500134e]
4.Shen J, Zhu Z. (2008) Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.. Curr Opin Mol Ther, 10 (3):(273-84). [PMID:18535935][10.1021/op500134e]
5.Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A. (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.. Cancer Immunol Immunother, 56 (10):(1637-44). [PMID:17410361][10.1021/op500134e]
6.Linke R, Klein A, Seimetz D. (2010) Catumaxomab: clinical development and future directions.. MAbs, 2 (2):(129-36). [PMID:20190561][10.1021/op500134e]
7.Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. (2010) Structural and functional characterization of the trifunctional antibody catumaxomab.. MAbs, 2 (3):(309-19). [PMID:20418662][10.1021/op500134e]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
